Floatz logo

Therapeutic Asset Ratings

470 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Capecitabine
Neoadjuvant Chemoimmunotherapy
Sun Yat-sen UniversityP2CCC (53)
Carboplatin
Disitamab Vedotin
Sun Yat-sen UniversityP2CCC (53)
Carboplatin
ERBB2 Mutation-Related Tumors
Sun Yat-sen UniversityP2CCC (53)
Carboplatin
RC48
Sun Yat-sen UniversityP2CCC (53)
Carboplatin
Toripalimab
Sun Yat-sen UniversityP2CCC (53)
Catequentinib
Efficacy and Safety
Sun Yat-sen UniversityP2CCC (53)
cc-5013
MSS Metastatic Colorectal Cancer
Sun Yat-sen UniversityP2CCC (53)
cc-5013
Peritoneal Metastasis
Sun Yat-sen UniversityP2CCC (53)
cc-5013
Peritoneal (Metastatic) Cancer
Sun Yat-sen UniversityP2CCC (53)
Cetuximab
Toxic Dermatosis
Sun Yat-sen UniversityP2CCC (53)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
CD5 Positive
Sun Yat-sen UniversityP2CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II
Concurrent Chemoradiotherapy
Sun Yat-sen UniversityP2CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II
Consolidation Therapy
Sun Yat-sen UniversityP2CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II
First-line Treatment
Sun Yat-sen UniversityP2CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II
Surufatinib
Sun Yat-sen UniversityP2CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II
Tislelizumab
Sun Yat-sen UniversityP2CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II
Toripalimab
Sun Yat-sen UniversityP2CCC (53)
Crisaborole
Cetuximab
Sun Yat-sen UniversityP2CCC (53)
Crisaborole
Toxic Dermatosis
Sun Yat-sen UniversityP2CCC (53)
Crizotinib
Mutation
Sun Yat-sen UniversityP2CCC (53)
Cyclophosphamide
CD5 Positive
Sun Yat-sen UniversityP2CCC (53)
Dabrafenib
BRAF V600 Mutation
Sun Yat-sen UniversityP2CCC (53)
Dabrafenib
Lung Cancer
Sun Yat-sen UniversityP2CCC (53)
Dabrafenib
MET Exon 14 Mutation
Sun Yat-sen UniversityP2CCC (53)
Dabrafenib
Mutation
Sun Yat-sen UniversityP2CCC (53)
Showing 151 to 175 of 470 assets
PreviousPage 7 of 19Next